Glioma/glioblastoma |
Phase 2 interventional (clinical trial) |
2023 |
Radiation, temozolomide, vitamin C |
Ongoing; ending in 2023 |
Clinical trial NCT0234435537
|
COVID-19 |
Randomized, open-label phase 4 trial |
2020 |
Hydroxychloroquine, azithromycin, zinc sulfate, doxycycline |
Ongoing; ending in 2020 |
Clinical trial NCT0437078238
|
Leukemia |
Phase 2 clinical trial |
2020 |
Azacitidine, vitamin C |
Ongoing; ending in 2020 |
Clinical trial NCT0339717339
|
Sepsis |
– |
2019 |
Vitamin D, standard antibiotic therapy |
Vitamin D supplementation improved sepsis score and decreased levels of high-sensitivity C-reactive protein |
Hagag et al (2019)40
|
Severe pneumonia |
Retrospective cohort study |
2018 |
Vitamin C, hydrocortisone, thiamine |
Compared with control group, adjunctive therapy group had lower hospital mortality and higher rate of recovery from severe pneumonia |
Kim et al (2018)41
|
Atopic dermatitis |
Randomized, double-blind, placebo-controlled clinical trial |
2018 |
Vitamin D3 (5000 IU/d), baseline therapy (topical steroid, soap substitute, and emollient) |
Treatment group had reduced atopic dermatitis severity score |
Sánchez-Armendáriz et al (2018)42
|
Hepatitis C |
Controlled randomized clinical trial |
2017 |
Vitamin C (orange juice), pegylated interferon combined with ribavirin |
Levels of liver enzyme aspartate aminotransferase decreased in patients who had high levels before the study |
Gonçalves et al (2017)43
|
Ehrlich ascites carcinoma |
Rodent study |
2017 |
Selenium, cyclophosphamide |
Selenium improved chemotherapeutic effect of cyclophosphamide |
Bhattacharjee et al (2017)44
|
Sensorineural hearing loss |
Nonblinded, noncontrolled study |
2015 |
Vitamin A (26 000 IU), vitamin C (200 mg), vitamin E (200 IU), selenium (50 μg), methylprednisolone (1 mg/kg), trimetazidine dihydrochloride (20 mg, 3 times daily) |
Treatment with vitamins A, C, and E and selenium was effective in restoring function after sudden idiopathic sensorineural hearing loss |
Kaya et al (2015)45
|